Showing results (31-40 of 50) with videos related to
Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|September 15, 2015
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumorsKelong Han, Jin Y Jin, Mathilde Marchand, et al.Epilepsy Research|March 21, 2009
Safety of an IV formulation of carbamazepineJeannine M Conway, James R White, Angela K Birnbaum, et al.Neuro-Oncology|February 17, 2010
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I studyNicholas Butowski, Susan M Chang, Kathleen R Lamborn, et al.Clinical Pharmacology in Drug Development|March 27, 2025
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P-Glycoprotein InhibitionHongxia Jia, T Eric Ballard, Liming Zhang, et al.Clinical Pharmacology and Therapeutics|November 16, 2023
Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for TucatinibIan E Templeton, Karen Rowland-Yeo, Hannah M Jones, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 31, 2023
The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) InhibitorRyan H Takahashi, Vikram Malhi, Bianca M Liederer, et al.Investigational New Drugs|August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 10, 2015
Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in HumansRyan H Takahashi, Edna F Choo, Shuguang Ma, et al.Anti-Cancer Drugs|November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumorsD Ross Camidge, S Gail Eckhardt, Lia Gore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancerMichael A Carducci, Luna Musib, Merrill S Kies, et al.Pageof 5